IMMX Stock Overview
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immix Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.21 |
| 52 Week High | US$7.75 |
| 52 Week Low | US$1.40 |
| Beta | 0.049 |
| 1 Month Change | -19.93% |
| 3 Month Change | -60.18% |
| 1 Year Change | 17.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.78% |
Recent News & Updates
Recent updates
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Nov 28
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
Mar 29Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans
Sep 13We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely
May 21Shareholder Returns
| IMMX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -23.5% | -4.7% | -3.7% |
| 1Y | 17.6% | -2.7% | 20.2% |
Return vs Industry: IMMX exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: IMMX underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| IMMX volatility | |
|---|---|
| IMMX Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMMX's share price has been volatile over the past 3 months.
Volatility Over Time: IMMX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 16 | Ilya Rachman | www.immixbio.com |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn’s disease. It has a clinical collaboration and supply agreement with BeiGene Ltd.
Immix Biopharma, Inc. Fundamentals Summary
| IMMX fundamental statistics | |
|---|---|
| Market cap | US$58.34m |
| Earnings (TTM) | -US$15.43m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs IMMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$15.43m |
| Earnings | -US$15.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMMX perform over the long term?
See historical performance and comparison